01—Abstract
Summary
Summary of the 8-K filed December 5, 2024. Cited figures are marked; the original filing is the authoritative source.
CVS Health Corporation (CVS) announced on December 3, 2024, that it has entered into an Underwriting Agreement to issue and sell a significant aggregate principal amount of junior subordinated notes.
Specifically, the company plans to issue $2.25 billiona of 7.000% Series A Junior Subordinated Notes due 2055 and $750 million of 6.750% Series B Junior Subordinated Notes due 2054. This offering is being conducted under the company's existing Shelf Registration Statement filed in May 2023. The anticipated closing date for this transaction is December 10, 2024, subject to customary closing conditions.
CVS Health expects to receive net proceeds of approximately $2.96 billionb from this offering, after accounting for underwriter discounts and estimated expenses. This capital raise will likely be used to fund general corporate purposes, although the specific use of proceeds is not detailed in this filing. Investors should note that these are junior subordinated notes, which carry a higher risk profile compared to senior debt.
02—Key points
Key Highlights
- CVS Health is raising approximately $2.96 billion in net proceeds through the issuance of junior subordinated notes.
- The offering consists of $2.25 billion in 7.000% Series A Junior Subordinated Notes due 2055.
- An additional $750 million in 6.750% Series B Junior Subordinated Notes due 2054 are also being issued.
- The notes are junior subordinated, indicating a lower priority in the capital structure in case of default.
- The sale is expected to close on December 10, 2024.
- The offering is conducted under a previously filed Form S-3ASR Shelf Registration Statement.
- The Underwriting Agreement is filed as an exhibit to the 8-K.
03—Questions
Frequently Asked Questions
What is the purpose of this debt issuance?
While the filing does not explicitly state the use of proceeds, this type of capital raise is typically for general corporate purposes, which could include refinancing existing debt, funding acquisitions, or supporting operational growth.
What are the terms of the notes being issued?
CVS Health is issuing $2.25 billion of 7.000% Series A Junior Subordinated Notes due 2055 and $750 million of 6.750% Series B Junior Subordinated Notes due 2054. These are junior subordinated notes, meaning they rank below other senior debt obligations of the company.
What is the expected closing date for this offering?
The closing of the sale of the notes is expected to occur on December 10, 2024, contingent upon the satisfaction of customary closing conditions outlined in the Underwriting Agreement.
What are the risks associated with investing in these junior subordinated notes?
As junior subordinated notes, these securities carry a higher level of risk compared to senior debt. In the event of bankruptcy or liquidation, holders of these notes would be paid after senior debt holders, meaning there is a greater risk of loss of principal and interest.
04—Continue